LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

Xuper™ obtained CE Certification

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that effective on 20 May 2021, the Group's self-developed Xuper™ Open Surgery Graft System ("**Xuper™**" or the "**Device**") has been granted with the CE certificate in Europe, which is intended for hybrid surgery therapy of patients with Stanford type A aortic dissection.

Stanford type A aortic dissection has become one of the main diseases that seriously endanger human health due to its high morbidity and high mortality rate. Compared with traditional surgery method, hybrid procedure has the advantages of shortening the operation cycle and causing less trauma to patients and it is becoming a current mainstream surgery method for the treatment of Stanford type A aortic dissection. However, some problems remain with the current hybrid procedure, such as long learning curve, too many intraoperative anastomoses, long time of deep hypothermia circulatory arrest (the "**DHCA**"), and causing too many postoperative complications in clinical application. Therefore, it is of great significance to develop a hybrid procedure stent system with shorter learning curve, shorter operation time and less postoperative complications.

Xuper™ consists of an open surgery stent graft and its delivery system. The stent has a unique branched structure, the angle and spacing of the branches can be adjusted and self-adapted to the shape of the blood vessel. The proximal three-layer structure design is more convenient for clamping by surgical forceps and anastomosis with the proximal end of the stent. Compared with the current stent products without branch structure used in hybrid procedure, Xuper™ significantly reduces the number of anastomoses during surgery, effectively shortens the time of DHCA and reduces postoperative complications and intraoperative mortality rate. At the same time, it shortens the learning curve of surgery and can be used by more doctors for more patients.

The group will continue with independent innovation and work with industry experts to advance the development and marketing of innovative medical device products to the benefit of patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 25 May 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.